Rhenman & Partners Asset Management AB Acquires New Holdings in Charles River Laboratories International, Inc. $CRL

Rhenman & Partners Asset Management AB acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 22,000 shares of the medical research company’s stock, valued at approximately $4,389,000.

Other institutional investors have also recently bought and sold shares of the company. Tema Etfs LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $26,000. Rothschild Investment LLC lifted its stake in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $42,000. Sfam LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $43,000. Finally, Activest Wealth Management lifted its stake in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several research reports. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Mizuho set a $192.00 target price on Charles River Laboratories International in a research note on Friday, May 8th. UBS Group boosted their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Evercore restated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $208.50.

Charles River Laboratories International Trading Down 0.4%

Shares of Charles River Laboratories International stock opened at $187.39 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $143.06 and a 12-month high of $228.88. The stock has a market cap of $9.03 billion, a P/E ratio of -49.84, a P/E/G ratio of 2.15 and a beta of 1.46. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The business’s 50 day moving average is $173.50 and its 200-day moving average is $182.41.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the prior year, the business posted $2.34 EPS. The business’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.